Literature DB >> 21986150

Difference in pre- and postchemotherapy vascular endothelial growth factor levels as a prognostic indicator in osteosarcoma.

Y Qu1, J Xu, T Jiang, H Zhao, Y Gao, C Zheng, X Shi.   

Abstract

This retrospective analysis examined the difference in pre- and postchemotherapy levels of vascular endothelial growth factor (VEGF) as an indicator of osteosarcoma prognosis. VEGF protein levels were assessed immunohistochemically in primary tumour samples from 61 osteosarcoma patients diagnosed between February 2001 and July 2005. The difference in pre- and postchemotherapy VEGF protein reduction levels was categorized into weak (23 patients) and strong (38 patients). The 5-year survival rate was significantly lower in the weak VEGF reduction group (34.8%) than in the strong VEGF reduction group (73.7%). The weak VEGF reduction group had significantly higher rates of metastasis and recurrence. Multivariate analysis confirmed that the change in VEGF was an independent and significant factor for predicting a good prognosis. The analysis of VEGF will enable clinicians to tailor surgery and chemotherapy regimens more appropriately, earlier in the disease process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986150     DOI: 10.1177/147323001103900436

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

Review 1.  A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.

Authors:  Ding Chen; Ye-Jia Zhang; Ke-wei Zhu; Wan-Chun Wang
Journal:  Tumour Biol       Date:  2013-04-16

2.  Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.

Authors:  Marie-Dominique Tabone; Laurence Brugières; Sophie Piperno-Neumann; Marie-Ange Selva; Perrine Marec-Bérard; Hélène Pacquement; Cyril Lervat; Nadège Corradini; Jean-Claude Gentet; Rémy Couderc; Aurélie Chevance; Céline Mahier-Ait Oukhatar; Natacha Entz-Werle; Jean-Yves Blay; Marie-Cecile Le Deley
Journal:  BMC Cancer       Date:  2017-06-15       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.